RTTNews | Jul 6, 2021 10:26AM EDT

10:25 Tuesday, July 6, 2021 (RTTNews.com) - NRx Pharmaceuticals (NRXP) said Tuesday that it is initiating clinical training of Nation of Georgia ICU physicians, in the use of intravenous ZYESAMI or Aviptadil- acetate for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI for use in phase 2/3 clinical trials, for patients suffering with COVID-19.

In addition, the company said that it has extended its ongoing phase 2/3 trial of inhaled ZYESAMI to Georgia, in Partnership with Denk Pharma (Georgia), and Cromos, LLC.

NRx expects to ship clinical drug supplies to Georgia within two weeks. The development of intravenous Aviptadil-acetate, in non-GMP form was partially-funded by a collaboration agreement with Relief Therapeutics.

Read the original article on RTTNews ( https://www.rttnews.com/3207218/nrx-initiates-emergency-use-training-and-extends-phase-2-3-inhaled-zyesami-trial-in-georgia.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved